Evotec SE's revenue per share for the
three
months ended in Sep. 2024 was €1.04.
Evotec SE's revenue per share for the trailing twelve months (TTM) ended in Sep. 2024 was €4.38.
Warning Sign:
Evotec SE revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Evotec SE was -5.60% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 10.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 12.00% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 23.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Evotec SE's Revenue per Share or its related term are showing as below:
XTER:EVT'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -30.4 Med: 13 Max: 40
Current: 10.7
During the past 13 years, Evotec SE's highest 3-Year average Revenue Per Share Growth Rate was 40.00% per year. The lowest was -30.40% per year. And the median was 13.00% per year.
XTER:EVT's 3-Year Revenue Growth Rate is ranked better than 62.57% of 911
companies
in the Drug Manufacturers industry
Industry Median: 6.4
vs XTER:EVT: 10.70
Evotec SE Revenue per Share Historical Data
The historical data trend for Evotec SE's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Evotec SE's Revenue per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's PS Ratio distribution charts can be found below:
* The bar in red indicates where Evotec SE's PS Ratio falls into.
Evotec SE Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Evotec SE's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (XTER:EVT) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Evotec SE Revenue per Share Related Terms
Thank you for viewing the detailed overview of Evotec SE's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTER:EVT has been successfully added to your 